Short answer
Incyte (INCY) filed an 8-K current report with the SEC on March 6, 2026 reporting Item 8.01 (Other Events). FDA issued CRL for Zynyz's NSCLC indication, blocking approval of a significant potential label expansion.
Incyte 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA issued CRL for Zynyz's NSCLC indication, blocking approval of a significant potential label expansion
- CRL sole issue: manufacturing compliance at Catalent Indiana (Novo Nordisk-owned fill-finish facility); NOT drug efficacy or safety
- Zynyz's Phase 3 POD1UM-304 NSCLC data remains intact, preserving resubmission pathway once facility issues resolved
- Timeline risk: resubmission depends on Catalent Indiana remediation pace, which Incyte does not control
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Incyte 8-K filings
Get the next INCY 8-K as it lands
Follow INCY for push alerts, or ask the research agent what this filing means.